Stifel Nicolaus Reaffirms Their Buy Rating on Xenon (XENE)
In a report released today, Paul Matteis from Stifel Nicolaus maintained a Buy rating on Xenon, with a price target of $66.00.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Matteis covers the Healthcare sector, focusing on stocks such as Biogen, uniQure, and Alnylam Pharma. According to TipRanks, Matteis has an average return of 14.7% and a 49.39% success rate on recommended stocks.
In addition to Stifel Nicolaus, Xenon also received a Buy from Wells Fargo’s Benjamin Burnett in a report issued today. However, on the same day, TipRanks – xAI reiterated a Hold rating on Xenon (NASDAQ: XENE).
Based on Xenon’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $105.26 million. In comparison, last year the company had a GAAP net loss of $65.69 million
Read More on XENE:
Disclaimer & DisclosureReport an Issue
- Xenon Pharmaceuticals price target raised to $49 from $48 at Wells Fargo
- Xenon Highlights 2025 Results and Expands Late-Stage Pipeline
- Xenon Pharmaceuticals reports Q4 EPS ($1.31), consensus ($1.21)
- Xenon Pharmaceuticals options imply 24.8% move in share price post-earnings
- Is XENE a Buy, Before Earnings?
